Thanks! You've successfully subscribed to the BONEZONE®/OMTEC® Monthly eNewsletter!

Please take a moment to tell us more about yourself and help us keep unwanted emails out of your inbox.

Choose one or more mailing lists:
BONEZONE/OMTEC Monthly eNewsletter
OMTEC Conference Updates
Advertising/Sponsorship Opportunities
Exhibiting Opportunities
* Indicates a required field.

Evonik Signs Global Agreement, Expands RESOMER Portfolio

The move positions RESOMER as the reportedly largest, most differentiated portfolio of functional biomaterials for implantable devices.   

Evonik signed an exclusive global agreement with ITV Denkendorf Produktservice (ITVP), a Germany-based R&D entity and manufacturer of medical-textile materials.

Per agreement terms, Evonik will expand its RESOMER® portfolio with a new platform of glycolide-based polymers suitable for production of monofilaments and multifilaments to develop high-performance textile-based implantable products designed for rapid degradation, such as sutures, scaffolds, etc.

Polymers in the platform can be tailored to match target applications' mechanical properties (tensile strength, low bending stiffness or elasticity) and degradation rates (from less than a month to two months or more). Additional customization options are available upon request.

Evonik will leverage its technical capabilities in polymer processing and advanced application laboratories in the U.S., Germany and China, as well as the expertise of ITVP, to support customers in development, analytical testing and scale-up of their textile-based products.

“With this expansion into polymers for textile-based medical devices, Evonik continues to strengthen its position as a preferred global partner for medical device companies. Together with other recently launched biomaterial innovations including PLA-PEG copolymers, filaments for 3D printing and surface modification technologies, our RESOMER portfolio is now the world’s largest and most differentiated portfolio of biomaterials for use across orthopedic, vascular and wound closure applications,” said Dr. Jean-Luc Herbeaux, SVP and General Manager of the Health Care business line of Evonik.